Die Aktie von Valneva konnte in den letzten Tagen aufgrund von positiven Impfstoffdaten steigen. Denn die jüngsten Studienergebnisse von Valneva wirken vielversprechend: Demnach wies das Covid-19-Vakzin des französisch-österreichischen Konzerns in einer klinischen Phase-3-Studie mit mehr als 4000 Teilnehmerinnen und Teilnehmern einen besseren Immunschutz auf als jener von Astra-Zeneca. Zudem berichteten die Probandinnen und Probanden ab…
| Cookie | Dauer | Beschreibung |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
